News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PROLX Pharmaceuticals Acquires Worldwide Development And Commercialization Rights For Novel Phosphatidylinositol-3-Kinase Inhibitors


10/19/2005 5:10:51 PM

ProlX Pharmaceutical Corp. has received the exclusive worldwide license for the development and marketing rights to the phosphatidylinositol-3-kinase (PI-3K) inhibitor wortmannin and semi-synthetic viridin analogues covered in a number of patents jointly owned by the University of Arizona, the University of Pittsburgh and the Burnham Institute. Under the terms of this agreement, ProlX Pharmaceuticals will share revenues with these institutions from the successful commercialization of the agents covered under the licensed patents.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES